BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28374831)

  • 21. CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients.
    Hosen N; Matsuoka Y; Kishida S; Nakata J; Mizutani Y; Hasegawa K; Mugitani A; Ichihara H; Aoyama Y; Nishida S; Tsuboi A; Fujiki F; Tatsumi N; Nakajima H; Hino M; Kimura T; Yata K; Abe M; Oka Y; Oji Y; Kumanogoh A; Sugiyama H
    Leukemia; 2012 Sep; 26(9):2135-41. PubMed ID: 22430638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enrichment of circulating myeloma cells by immunomagnetic beads combined with flow cytometry for monitoring minimal residual disease and relapse in patients with multiple myeloma.
    Wang N; Tesfaluul N; Li J; Gao X; Liu S; Yue B
    Ann Hematol; 2019 Dec; 98(12):2769-2780. PubMed ID: 31748925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of CD138 Magnetic Bead-based Positive Selection on Bone Marrow Plasma Cell Surface Markers.
    Bansal R; Kimlinger T; Gyotoku KA; Smith M; Rajkumar V; Kumar S
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e48-e51. PubMed ID: 32873534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.
    Ndacayisaba LJ; Rappard KE; Shishido SN; Ruiz Velasco C; Matsumoto N; Navarez R; Tang G; Lin P; Setayesh SM; Naghdloo A; Hsu CJ; Maney C; Symer D; Bethel K; Kelly K; Merchant A; Orlowski R; Hicks J; Mason J; Manasanch EE; Kuhn P
    Curr Oncol; 2022 Apr; 29(5):2954-2972. PubMed ID: 35621632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
    Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
    Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
    Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
    Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
    Kim D; Park CY; Medeiros BC; Weissman IL
    Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
    Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
    Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD138
    Wu D; Zhang P; Li F; Shen Y; Chen H; Feng Y; He A; Wang F
    Aging (Albany NY); 2020 Nov; 12(22):23067-23081. PubMed ID: 33197893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double CD38
    Mykytiv V; Alwaheed A; Mohd Hashim NA
    Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
    Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
    J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometry assessment of in vitro generated CD138+ human plasma cells.
    Itoua Maïga R; Lemieux J; Roy A; Simard C; Néron S
    Biomed Res Int; 2014; 2014():536482. PubMed ID: 24689045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Robust isolation of malignant plasma cells in multiple myeloma.
    Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
    Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
    Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
    Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.
    Muz B; de la Puente P; Azab F; Luderer MJ; King J; Vij R; Azab AK
    Br J Haematol; 2016 Apr; 173(1):70-81. PubMed ID: 26729247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma.
    Reid S; Yang S; Brown R; Kabani K; Aklilu E; Ho PJ; Woodland N; Joshua D
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e190-6. PubMed ID: 20201998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulus-Responsive Microfluidic Interface Enables Efficient Enrichment and Cytogenetic Profiling of Circulating Myeloma Cells.
    Liu Y; Su R; Song J; Yu X; Lin S; Zhu Z; Yang Y; Zhang M; Yang L; Zhang H; Xu X; Yang C
    ACS Appl Mater Interfaces; 2021 Apr; 13(13):14920-14927. PubMed ID: 33755428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
    Joshi R; Horncastle D; Elderfield K; Lampert I; Rahemtulla A; Naresh KN
    J Clin Pathol; 2008 Feb; 61(2):213-6. PubMed ID: 17526802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.